1. Medtech Insight
  2. >>Business

Robotic-Assisted Surgery: Taking MIS By Storm

Robotically assisted surgical devices are one of the hottest and fastest growing segments in the market for minimally invasive surgery (MIS) products, with a global market opportunity projected to reach more than $10 billion by 2021. A growing number of competitors hope to capture share and further expand the market by targeting key procedures and geographies with next generation robotic surgery systems and robotic-like technologies designed to improve outcomes and enable more complex procedures to be performed via an MIS approach.

In the market for minimally invasive surgery (MIS) products, one of the hottest and fastest growing segments is robotically assisted surgical devices (RASD). In the last 15 years, Intuitive Surgical Inc., the market leader in RASD for soft tissue applications, has steadily increased penetration into MIS and demonstrated that robotic-assisted surgery is not just a gimmick or niche market, but a multibillion dollar global market opportunity that is projected to reach more than $10 billion by 2021.

In 2015 alone, Intuitive reported $2.38 billion in revenues and 652,000 procedures performed with its da Vinci Surgical System, up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Execs On The Move: August 4–8, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

 
• By Elizabeth Orr

The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 
• By Brian Bossetta

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.